A World Without Infectious Disease

Literature archive related to Vir science

Antibody Platform

Transfer transcriptomic signatures for infectious diseases
Julia di Iulioa, Istvan Barthaa, Roberto Spreaficoa, et al
PNAS, 2021

MP-NeRF: A massively parallel method for accelerating protein structure reconstruction from internal coordinates
Eric Alcaide, Stella Biderman, Amalio Telenti, et al
bioRxiv, 2021

Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell, 2021

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al
MedRxiv 2021

The need for global access to biomedical innovations during pandemics
Rajesh Gupta
Nature, 2021

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
Andrea L. Cathcart, Colin Havenar-Daughton, Florian A. Lempp, et al
bioRxiv, 2021

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr
bioRxiv 2021

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
Tyler N. Starr, Nadine Czudnochowski, Fabrizia Zatta
bioRxiv 2021

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
bioRxiv, 2021

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
bioRxiv, 2021

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell, 2021

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
Michael Diamond, Rita Chen, Xuping Xie, et al
Research Square, 2021

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
Dami Collier, Anna De Marco, Isabella Ferreira, et al
medRxiv, 2021

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Emma C Thomson, Laura E Rosen, James G Shepherd, et al
Cell, 2021

Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland
Luca Piccoli, Paolo Ferrari, Giovanni Piumatti, et al.
The Lancet Regional Health - Europe

Advancing new tools for infectious diseases
Rajesh Gupta
Science, 2020

Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
Stylianos Bournazos, Davide Corti, Herbert W. Virgin & Jeffrey V. Ravetch
Nature, 2020

Vir Effector Function Deep Dive.
Vir Biotechnology, Inc., 2020

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo
Alexandra Schäfer, Frauke Muecksch, Julio C. C. Lorenzi, et al
BioRxiv, 2020

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
M. Alejandra Tortorici, Martina Beltramello, Florian A. Lempp, et al
Science, 2020

Mapping Neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
Luca Piccoli, Young-Jun Park, M. Alejandra Tortorici, et al
Cell, 2020

A combination of two human monoclonal antibodies cures symptomatic rabies
Guilherme Dias de Melo, Florian Sonthonnax, Gabriel Lepousez, et al
EMBO Molecular Medicine, 2020

A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Ann M. Arvin, Katja Fink, Michael A. Schmid, et al
Nature, 2020

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto, Young-Jun Park, Martina Beltramello, et al
Nature, 2020

Developing therapeutic monoclonal antibodies at pandemic pace
Brian Kelley
Nature Biotechnology, 2020

Tackling influenza with broadly neutralizing antibodies
Davide Corti, Antonio Lanzavecchia
Current Opinion in Virology, 2017

Fcg receptor function and the design of vaccination strategies
Stylianos Bournazos and Jeffrey V. Ravetch
Immunity, 2017

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Davide Corti, Antonio Lanzavecchia, Nancy J. Sullivan
Science, 2016

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu, M.D. et al
February, 2019

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
Davide Corti, Antonio Lanzavecchia
Nature, 2013

T Cell Platform

CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination
Klaus Frueh, Louis Picker
Current Opinion in Immunology, 2017

Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E
Scott G. Hansen, Louis J. Picker
Science, 2016

Innate Immunity Platform

Sphingolipid biosynthesis induces a conformational change in the murine norovirus receptor and facilitates viral infection
Robert C. Orchard, Herbert W. Virgin
Nature Microbiology, 2018

Discovery of a proteinaceous cellular receptor for a norovirus
Robert C. Orchard, Herbert W. Virgin
Science, 2016

Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon NOX2 and autophagy proteins
Jennifer Martinez, Herbert W. Virgin, Douglas R. Green
Nature Cell Biology, 2015

Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection
Jacqueline M. Kimmey, Herbert W. Virgin, Christina L. Stallings
Nature, 2015

siRNA Platform

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Maja M. Janas, Vasant Jadhav
Nature Communications, 2018